Clinical Observation of Renal Function Reactivation Following a GRAS-Based Protocol in Patients With Chronic Kidney Disease and Long-Term Renal Arrest.

This observational study documents the impact of a specific oral protocol (based on FDA-GRAS ingredients) on patients with Stage 5 Chronic Kidney Disease (CKD). The study observes 8 participants, including 6 with residual renal function and 2 patients with long-term total renal arrest (16 years and 22 years of anuria). The primary focus is monitoring the restoration of urine output and changes in renal biological markers.

NCT Number	NCT07555327
Lead Sponsor	Amar h Zireg
Conditions	End-Stage Renal Disease (ESRD) Chronic Kidney Disease, Stage 5 Renal Regeneration Anuria Diabetic Nephropathy, Anuria, End-Stage Renal Disease (ESRD), Chronic Kidney Disease, Stage 5, Renal Regeneration, Diabetes, Diabetes Complications, Non Diabetic Patients +1 more
Enrollment	8 participants
Start Date	2026-02-02
Primary Completion	2026-04-15 (estimated)
Study Completion	2026-05-19 (estimated)
Updated on ClinicalTrials.gov	2026-05-27